Mandate

Vinge has advised Lantmännen in connection with the divestment of Lantmännen Agrovärme

Vinge has advised Lantmännen in connection with the divestment of Lantmännen Agrovärme to Solör Bioenergi.

Lantmännen Agrovärme produces, distributes, and sells district heating from 19 plants in the southern and central parts of Sweden to approximately 1100 customers. Lantmännen Agrovärme's strategy is to contribute to a circular economy. About 95 percent of the heat from Lantmännen Agrovärme comes from the combustion of locally produced biofuels, such as wood chips, energy forests, wood pellets and rest products from agriculture.

Vinges team consisted primarily of Christina Kokko, Peter Sundgren, Ellinor Wargenbrant and Elsie Nassar (M&A), Eva Fredriksson (Commercial Agreements), Sara Strandberg (Employment) and Julia Hagelberg (Project assistant).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024